[Webinar] Enterprise R&D Transformation Case Studies: Biogen and Sanofi

Ayman Ismail holds a PhD in Molecular Biophysics. In his role as Principal Scientist – Lab Head at Sanofi, he leads biologics-based therapeutic discovery projects. He also manages a protein production and characterization group supporting the entire Rare and Neurologic Disease research department. Ismail was responsible for Benchling deployment at Bioverativ in 2017. After Sanofi’s acquisition of Bioverativ, he played a crucial role in Sanofi’s decision to transition to Benchling.

David Sexton is Biogen's Senior Director of Genome Technology and Informatics and handles all NGS sequencing, NGS data analysis and information systems. Sexton has more than 25 years of experience in genomics and informatics and was the Head of Genome Informatics at NIBR where he focused on data architecture and infrastructure for genomics data. He is deeply involved in the FAIR data community, has worked in both BioPharma and academia, and is a member of the Pistoia Alliance's steering committee, UK Biobank and FinnGen. He currently leads a data infrastructure change at Biogen to help data scientists find and access research data for meta-analysis and empower bench scientists to query and view data relevant to their work.

Loren Perelman spent much of his career focused on helping organizations make better use of their primary asset, data, by improving methods of collection and utilization. Prior to Benchling, Perelman was Vice-President of Scientific Solutions at Riffyn, working with various customers in the biotech and biopharma spaces. Before Riffyn, he spent more than a decade leading the R&D, PD and manufacturing teams in the same spaces, with a focus on quality, analytical chemistry and stats/modeling. His education includes a PhD in Materials Science from UCSD and a B.S. in Chemistry from Harvey Mudd College.